New Data Shows HIV Therapy Tipranavir (Aptivus®) Is Effective And Well Tolerated In Children

Boehringer Ingelheim presented new 100 week data at the International AIDS Conference demonstrating Aptivus® (tipranavir) long-term efficacy and safety in treatment-experienced children. Results from this two-year study show that Aptivus® enabled the children to achieve sustained virologic and immunologic responses and was a well-tolerated antiretroviral therapy.

More: continued here

Filed under: Clinical Trials on August 11th, 2008